Cancer
Recent research conducted by scientists at the Queensland University of Technology has shed light on the potential of mesoporous silica nanoparticles (MSNs) in cancer gene therapy. The study, published in the journal Pharmaceutics, explores the therapeutic applications of MSNs in cancer treatment, with a focus on overcoming the challenges of
Cancer
Research on non-small cell lung cancer (NSCLC) has led to the discovery of tumor-specific B-cell gene co-expression networks, which are critical for understanding the disease progression and treatment outcomes. According to the study, the processes underlying B-cell dysfunction and their prognostic importance in NSCLC are unknown. The research team, led
Cancer
Researchers from the Faculty of Pharmacy conducted a comprehensive review of the literature on immunotherapy drugs, known as immune checkpoint inhibitors (ICIs), in the treatment of cancer. According to the study, ICIs work by blocking checkpoint proteins, specifically targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1)
Cancer
A pilot clinical trial conducted at Memorial Sloan Kettering/MD Anderson Cancer Centers has shed light on the effectiveness of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, in combination with nivolumab, a PD-1 blockade, in patients with locally advanced or metastatic high-grade sarcoma. The trial aimed to assess the efficacy and
Cancer
Researchers from Weill Cornell Medicine and the New York Genome Center, in collaboration with Oxford Nanopore Technologies, have made a groundbreaking discovery in understanding the three-dimensional structure of the human genome. By developing a novel method using genome-scale nanopore sequencing, they have demonstrated that cell function, including gene expression, is
Cancer
Research conducted by the Duke Cancer Institute has led to the development of a novel combination of monoclonal antibodies, which demonstrated significant efficacy in patients with advanced non-small cell lung cancer (NSCLC). The study, titled "A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With
Cancer
Enlivex Therapeutics, a clinical-stage macrophage reprogramming immunotherapy company, has initiated the first clinical trial of Allocetra in patients with cancer. The trial is a Phase I/II study evaluating the safety and potential efficacy of Allocetra combined with standard-of-care chemotherapy in patients with peritoneal metastases arising from solid cancer. Peritoneal
Cancer
Researchers at Baylor College of Medicine in Houston, Texas, have made a significant breakthrough in cancer gene therapy with the development of HydrAd, a helper-dependent adenovirus that targets multiple immune pathways for cancer treatment. According to a new report, HydrAd has the potential to provide a promising cancer immunotherapy agent
Cancer
Researchers have been focusing on the primary erythroid defect in beta-thalassemia (BThal) and sickle cell disease (SCD), rather than studying the hematopoietic stem cells (HSCs) and bone marrow (BM) microenvironment. The quality and engraftment of HSCs depend on the BM microenvironment, influencing the outcome of HSC transplantation (HSCT) in both
Cancer
A recent study has shed light on the public's understanding of human papillomavirus (HPV)-associated oropharyngeal cancer (OPC), highlighting significant communication gaps between the public and healthcare professionals regarding this disease. The research, conducted by Howard University, analyzed 3,112 tweets about OPC collected over 40 weeks using
Cancer
Researchers at Wuhan University have made significant progress in applying nanotechnology to enhance cancer immunotherapy, with a focus on promoting immunogenic cell death. This approach has shown promise in inducing a strong antitumor immune response, which can be enhanced by combining it with various therapies such as chemotherapy, radiotherapy, and
Cancer
Researchers from the University of Oxford have discovered that decitabine, a DNA methyltransferase inhibitor, can increase the expression of neoantigens and cancer testis antigens in glioblastoma cells, making them more susceptible to T cell-mediated toxicity. This breakthrough finding has significant implications for the treatment of glioblastoma, a highly aggressive and
